Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics

Psychiatry Research

Volumn 177, Issue 1-2, 2010, Pages 77-83

  Caligiuri, Michael P ^a   Teulings, Hans Leo ^b   Dean, Charles E ^c   Niculescu, Alexander B ^d,e   Lohr, James B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NeuroScript LLC   (United States)

^c VA MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotics; Extrapyramidal side effects; Handwriting movements; Instrumentation; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAND MOVEMENT; HANDWRITING; HUMAN; KINEMATICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; QUANTITATIVE DIAGNOSIS; TARDIVE DYSKINESIA; VALIDITY;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIOMECHANICS; CROSS-SECTIONAL STUDIES; FEMALE; HANDWRITING; HUMANS; MALE; MIDDLE AGED; MOVEMENT; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 77952098666     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.07.005     Document Type: Article

References (34)

1. Arnt J. Pharmacological differentiation of classical and novel antipsychotics. International Clinical Psychopharmacology 1998, 13(Suppl 3):S7-S14.
2. Barnes T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989, 154:672-676.
3. Caligiuri M.P. Instrumental measurement of tardive dyskinesia. Neuroleptic-Induced Movement Disorders: A Comprehensive Survey 1997, 241-258. Cambridge University Press. R. Yassa, N.P.V. Nair, D.V. Jeste (Eds.).
4. Caligiuri M.P., Jeste D.V., Lacro J.P. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs and Aging 2000, 17:363-384.
5. Caligiuri M.P., Teulings H.L., Filoteo J.V., Song D., Lohr J.B. Quantitative measurement of handwriting in the assessment of drug-induced Parkinsonism. Human Movement Science 2006, 25:510-522.
6. Caligiuri, M.P., Teulings, H.L., Dean, C.E., Niculescu, A.B., Lohr, J.B., 2009. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. Human Movement Science 28 (5), 633-642.
7. Chrzanowski W., Marcus R., Torbeyns A., Nyilas M., McQuade R. Effectiveness of long-term aripiprazole therapy in patients with acute relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006, 189:259-266.
8. Cronbach L.J. Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16:297-334.
9. Davies M., Sheffler D., Roth B. Aripiprazole: a novel atypical antipsychotic drug with a unique robust pharmacology. CNS Drugs Review 2004, 10:317-336.
10. Gallucci R.M., Phillips J.G., Bradshaw J.L., Vaddadi K.S., Pantelis C. Kinematic analysis of handwriting movements in schizophrenic patients. Biological Psychiatry 1997, 41:830-833.
11. Gerken A., Wetzel H., Benkert O. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients. Pharmacopsychiatry 1991, 24:132-137.
12. Guy, W., 1976. Abnormal Involuntary Movement Scale (AIMS) In: ECDEU Assessment Manual for Psychopharmacology, rev. ed. DHEW Pub. No. (ADM. 76-338). National Institute of Mental Health, Rockville, MD, pp. 534-537.
13. Haase H.J. Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs. Review of Canadian Biology 1961, 20:425-449.
14. Haase H.J. The purely neuroleptic effects and its relation to the "neuroleptic threshold". Acta Psychiatrica Belgium 1978, 78:19-36.
15. Kane J.M., Leucht S., Carpenter D., Docherty J.P. The Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders: introduction, methods, commentary, and summary. Journal of Clinical Psychiatry 2003, 64(Supplement 12):5-19. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.
16. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry 2001, 50:873-883.
17. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia. A randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry 1999, 60:107-115.
18. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 32:261-276.
19. 2 receptor partial agonism?. American Journal of Psychiatry 2007, 164:1310-1312.
20. Künstler U., Juhnhold U., Knapp W.H., Gertz H.J. Positive correlation between reduction in handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Research 1999, 90:31-39.
21. Künstler U., Hohdorf K., Regenthal R., Seese A., Gertz H.J. Diminution of hand writing area and D2-dopamine receptor blockade: results from treatment with typical and atypical neuroleptics. Nervenarzt 2000, 71:373-379.
22. Lohr J.B., Caligiuri M.P. Quantitative instrumental assessment of tardive dyskinesia: a review. Neuropsychopharmacology 1992, 6:231-239.
23. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., Iwamoto T. Aripiprazole in the treatment of schizophrenia. Safety and tolerability in short-term, placebo controlled trials. Schizophrenia Research 2003, 61:123-136.
24. Meyer D.E., Abrams R.A., Kornblum S., Wright C.E., Smith J.E.K. Optimality in human motor performance: ideal control of rapid aimed movements. Psychological Review 1988, 95:340-370.
25. Miller D.D., Caroff S.N., Davis S.M., Rosenheck R.A., McEvoy J.P., Saltz B.L., Riggio S., Chakos M.H., Swartz M.S., Keefe R.S., Stroup T.S., Lieberman J.A. Extrapyramidal side-effects of antipsychotics in a randomized trial. British Journal of Psychiatry 2008, 193:279-288. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE Investigators).
26. Regenthal R., Kunstler U., Hesse S., Sabri O., Preiss R. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. International Journal of Clinical Pharmacology and Therapeutics 2005, 43:370-378.
27. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970, 212(Suppl 44):11-19.
28. Tandon R., Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Annals of Clinical Psychiatry 2002, 14:123-129.
29. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002, 161:23-45. (Erratum in: CNS Drugs 2003;17, 202).
30. Teeken J.C., Adam J.J., Paas F.G.W.C., Van Boxtel M.P.J., Houx P.J., Jolles J. Effect of age and gender on discrete and reciprocal aiming movements. Psychobiology and Aging 1996, 11:195-198.
31. Teulings H.L., Maarse F.J. Digital recording and processing of handwriting movements. Human Movement Science 1984, 3:193-217.
32. Teulings H.L., Contreras-Vidal J.L., Stelmach G.E., Adler C.H. Coordination of fingers, wrist, and arm in Parkinsonian handwriting. Experimental Neurology 1997, 146:159-170.
33. Weiden P.J. EPS profiles: the atypical antipsychotics are not all the same. Journal of Psychiatric Practice 2007, 131:13-24.
34. Yang S.Y., Kao Yang Y.H., Chong M.Y., Yang Y.H., Chang W.H., Lai C.S. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clinical Pharmacology and Therapeutics 2007, 81:586-594.